The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. All who are in a position to control the content of an education activity (including their spouse or partner) are required to disclose to ACG all relevant financial relationships in any amount occurring in the past 12 months with any commercial interest that may create a conflict of interest related to the subject matter of an education activity. Safeguards against commercial bias have been put in place by ACG. Anyone who refuses to disclose relevant financial relationships will be disqualified. ACG ensures any conflicts of interest are resolved before the educational activity occurs and discloses all relevant financial relationships to the learners prior to the beginning of an education activity.
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, consumed by, or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant Financial Relationships
The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The ACCME has not set a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The vast majority of the material presented in the ACG Education Universe has previously been presented in lecture or other learning format, and author disclosure information reflects the content and format for disclosure provided by the presenter as of the date that his/her material was presented and captured electronically, and in compliance with ACG policies and ACCME requirements in effect as of that date of presentation. Author and planner conflicts were identified and resolved in accordance with ACG’s Policies and Procedures on Identifying and Resolving Conflicts of Interest.
Unapproved 'Off-Label' Usage Policy
If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the faculty member shall be required to disclose that the product is either investigational or it is not labeled for the usage being discussed.
David T. Rubin, MD, FACG (Editor)
Advisory Committee/Board Member: CCFA
Consultant: AbbVie Pharmaceuticals, Abgenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceuticals, Galen Pharma/Atlantica, Genentech, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), GSK, Janssen, Lilly, Narrow River Mgmt., Pfizer, Prometheus, Reistone, Shire, Takeda, Techlab, Inc.
Grant/Research Support: AbbVie Pharmaceuticals, Genentech, Janssen, Prometheus Laboratories, Shire, Takeda
Co-Founder: GoDuRn, LLC (no financial support received)
Co-Founder, CFO: Cornerstones Health (non-profit medical education company)
Royalties: Slack Publications
Brooks D. Cash, MD, FACG (Associate Editor)
Consultant: Allergan, Salix
Speakers Bureau: Allergan, Salix
Kenneth R. DeVault, MD, FACG (Associate Editor)
Board of Directors: Mayo Clinic
Consultant: Phathom Phamaceuticals
Research Grant: Ironwood
Other: Ironwood Multicenter study where we are a site Phathom Central reading of endoscopy images
Seth A. Gross, MD, FACG (Associate Editor)
Consultant: Boston Scientific, Cook, Microtech
Speaker's Bureau: CDX Diagnostics, Olympus
Stockholder: CSA Medical
Lisa B. Malter, MD, FACG (Associate Editor)
I have served as the PI on educational grants that support our IBD fellowship and other educational programming at NYU. The supporting companies are: AbbVie, Janssen, Pfizer, Prometheus, and Takeda I have directed educational programs that have been supported by the following companies: AbbVie, Gilead, Janssen, Merck, Pfizer, Prometheus, Salix, and Takeda
Mitchell L. Shiffman, MD, FACG (Associate Editor)
Advisory Board: AbbVie, Gilead, Intercept, Mallinckrodt, Shionogi
Research Grant: Conatus, CymaBay, Dova, Enanta, Gilead, Intercept
Speakers Bureau AbbVie, Daiichi Sankyo, Easai, Gilead, Intercept, Shionogi
Thomas M. Attard, MD
Dr. Attard has indicated no relevant financial relationships.
Geoffrey L. Braden, MD, FACG
Advisory Board: Medscape Gastroenterology
Joseph G. Cheatham, MD, FACG
Dr. Cheatham has indicated no relevant financial relationships.
Thomas G. Cotter, MD
Dr. Cotter has indicated no relevant financial relationships.
Silvio W. de Melo, Jr., MD
Jami A.R. Kinnucan, MD
Advisory Board: AbbVie, Janssen, Pfizer
Consultant: Hemp CW
Noa Krugliak Cleveland, MD
Research Grant: Gastrointestinal Research Foundation
Tamara K. Lundberg, FNP, MSN
Ms, Lundberg has indicated no relevant financial relationships.
Rajiv T. Majithia, MD, FACG
Dr. Majithia has indicated no relevant financial relationships.
Anjali Malkani, MD
Dr. Malkani has indicated no relevant financial relationships.
Mark C. Mattar, MD, FACG
Speaker's Bureau: AbbVie, Pfizer
Inessa Normatov, MD
Dr. Normatov has indicated no relevant financial relationships.
Sarah M. Ordway, MD
Dr. Ordway has indicated no relevant financial relationships.
Amit Patel, MD
Dr. Patel has indicated no relevant financial relationships.
Anjana A. Pillai, MD
Advisory Board: Exelixis, Genentech
Research Grant: Exact Sciences, Target Pharmasolutions
Speakers Bureau: Eisai Inc Simply Speaking Hepatitis
Kamron Pourmand, MD
Dr. Pourmand has indicated no relevant financial relationships.
Francisco C. Ramirez, MD, FACG
Dr. Ramirez has indicated no relevant financial relationships.
Zeeshan Ramzan, MD, FACG
Consultant: Boston Scientific
Mona Rezapour, MD
Dr. Rezapour has indicated no relevant financial relationships.
Neeral L. Shah, MD
Christina M. Steinhauser, DO
Dr. Steinhauser has indicated no relevant financial relationships.
Matthew J. Stotts, MD
Dr. Stotts has indicated no relevant financial relationships.
ACG Board of Trustees
Oversight of all educational programming content is conducted by the ACG Board of Trustees through a review and approval process. View the ACG Board of Trustees disclosure information by clicking on the link below.
All ACG staff in a position to control the content of a CME activity are required to complete ACG’s COI form annually. As of January 2017, all ACG staff in a position to control CME content have nothing to disclose.